An analysis of data from health insurance databases for patients with non-valvular atrial fibrillation treated with dabigatran etexilate or warfarin for prevention of stroke
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 24 Feb 2017
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin
- Indications Stroke
- Focus Therapeutic Use
- 24 Feb 2017 Results (n=21735)published in the Boehringer Ingelheim Pharmaceuticals media release.
- 11 Nov 2015 Interim results presented at the 88th Annual Scientific Sessions of the American Heart Association.
- 10 Nov 2015 According to a Boehringer Ingelheim media release, interim analysis results of this study were presented at the American Heart Association (AHA) Scientific Sessions 2015.